STOCK TITAN

Organon To Report First Quarter and Host Conference Call on May 4, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Organon (NYSE: OGN) is set to release its Q1 2023 financial results on May 4, 2023, before a scheduled webcast and conference call at 8:30 a.m. EDT. The live call can be accessed via the company's website, with a replay available two hours post-event. Institutional investors and analysts must register in advance to join the call.

Organon, headquartered in Jersey City, New Jersey, focuses on women's health, offering over 60 products across various therapeutic areas. The company aims to invest in innovation and strengthen its global presence, supporting growth and collaboration opportunities in the biopharmaceutical sector.

Positive
  • None.
Negative
  • None.

JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global women’s healthcare company will release its first quarter 2023 financial results on May 4, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.

Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: https://conferencingportals.com/event/jgIqShwa.

Following registration, participants will receive a confirmation email containing details on how to join the conference call, including dial-in information and a unique passcode and registrant ID. Pre-registration will allow participants to bypass an operator and be placed directly into the call.

About Organon
Organon is a global healthcare company with a focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, Twitter and Facebook.

Organon Media:

Karissa Peer

(614) 314-8094

Kate Vossen

(732) 675-8448

Organon Investor:

Jennifer Halchak

(201) 275-2711

Alex Arzeno

(203) 550-3972

Source: Organon & Co.

FAQ

When will Organon release its Q1 2023 financial results?

Organon will release its Q1 2023 financial results on May 4, 2023.

What time is the Organon conference call scheduled for?

The conference call is scheduled for 8:30 a.m. EDT on May 4, 2023.

How can I access the Organon Q1 2023 webcast?

The live call can be accessed via Organon's website at https://www.organon.com/investor-relations/events-and-presentations/.

Is pre-registration required for the Organon conference call?

Yes, institutional investors and analysts must register in advance to participate in the call.

What is Organon's business focus?

Organon focuses on improving women's health and has a portfolio of over 60 medicines across various therapeutic areas.

Where is Organon headquartered?

Organon is headquartered in Jersey City, New Jersey.

Organon & Co.

NYSE:OGN

OGN Rankings

OGN Latest News

OGN Stock Data

3.90B
256.95M
0.18%
81.71%
5.49%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
JERSEY CITY